ES Doce 80 Injection Combipack might cause serious allergic reactions and fluid retention if you had previously experienced allergic reactions with paclitaxel and cabazitaxel. These medicines contain polysorbate 80, an excipient. If you had any allergic reactions with medicines containing polysorbate 80, ES Doce 80 Injection Combipack is not recommended. Please consult your doctor for more information.

ES Doce 80 Injection Combipack is administered through an intravenous (IV) infusion. A healthcare professional usually gives it in a medical facility.

ES Doce 80 Injection Combipack may cause weight loss due to common side effects such as loss of appetite, nausea, vomiting, diarrhoea, and fatigue. But, in rare cases, some patients may experience fluid retention or increased hunger, which can lead to weight gain. Consult your doctor or pharmacist for personalized guidance if you have concerns about weight changes.

The duration of ES Doce 80 Injection Combipack treatment varies depending on the type of your cancer, dose of ES Doce 80 Injection Combipack, and your response to therapy. Typically, it is administered once every 3 weeks. Your doctor will determine the total length of treatment for you based on your specific situation.

No, it is advisable not to drink alcohol while taking ES Doce 80 Injection Combipack. Drinking alcohol during treatment may cause increased dizziness and drowsiness.

No, ES Doce 80 Injection Combipack is not available in pill form. It is available in two primary dosage forms: injection and powder for injection.

Before administering ES Doce 80 Injection Combipack, certain blood tests are required to ensure safe administration. These tests include a Complete Blood Count (CBC) to check blood cell counts, blood urea nitrogen (BUN) and creatinine levels to assess kidney function, liver function tests (LFTs) to evaluate liver health, and electrolyte level checks. Additionally, other tests may be required depending on individual patient needs and medical history. These blood tests help healthcare providers assess kidney and liver function and other vital parameters to ensure that ES Doce 80 Injection Combipack can be administered safely and effectively. Your healthcare provider will determine the necessary blood tests and monitoring requirements.

Hair loss caused by ES Doce 80 Injection Combipack is often reversible. While ES Doce 80 Injection Combipack can cause hair thinning or loss, hair growth returns once treatment is stopped. However, in some cases, hair loss may be permanent. Consult your healthcare provider for guidance and support if you're concerned about hair loss.

Dexamethasone is used with ES Doce 80 Injection Combipack to avoid toxicities.

ES Doce 80 Injection Combipack is a chemotherapy medication that belongs to the class of drugs known as anti-neoplastic/anticancer drugs. It is a cytotoxic agent that prevents the cancer cells from rapidly dividing and spreading.

ES Doce 80 Injection Combipack causes dizziness and drowsiness that may affect your ability to drive. So, do not drive or operate machinery if you experience these.

The common side effects of ES Doce 80 Injection Combipack may include vomiting, constipation, changes in taste, extreme tiredness, muscle, joint, or bone pain, hair loss, nail changes, increased eye tearing, sores in the mouth and throat, and redness, dryness, or swelling at the injection site. However, these symptoms usually diminish as your body adjusts to the medication. If these symptoms worsen, please consult a doctor for relief.

ES Doce 80 Injection Combipack is generally considered safe when following your doctor's advice. However, like all medications, it can have side effects and potential interactions with other drugs. It's important to follow your doctor's instructions and inform them of any pre-existing and existing medical conditions or medication history to avoid negative complications.

ES Doce 80 Injection Combipack contains Docetaxel, which belongs to the anticancer drugs.

Safety and efficacy of ES Doce 80 Injection Combipack have not been established in patients younger than 18 years.